Kyntra Bio presents Phase 1b/2 data on FG-3246 with enzalutamide in mCRPC
Kyntra Bio reported that investigator‑sponsored Phase 1b/2 data for FG‑3246 combined with enzalutamide in metastatic castration‑resistant prostate cancer will be presented at ASCO GU; the study included 44 patients and showed a composite response rate of 21% overall and median radiographic progression‑free survival of 7.0 months (10.1 months in patients with one prior ARPI).
